Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS181 for Severe COVID-19
NCT04324489Completed
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of DAS181 in coronavirus disease 2019 (COVID-19), sponsored by Renmin Hospital of Wuhan University. Primary endpoints: Improved clinical status at Day 14 and Return to room air at Day 14. Started Mar 2020; status: completed.
02
Drugs
DAS181
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04324489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324489.